Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-019905
Filing Date
2025-02-13
Accepted
2025-02-13 16:15:28
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9958
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 96939
  Complete submission text file 0000950170-25-019905.txt   145638
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Subject) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-79364 | Film No.: 25620473
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ONE VANDERBILT AVENUE, 26TH FLOOR NEW YORK NY 10017
Business Address ONE VANDERBILT AVENUE, 26TH FLOOR NEW YORK NY 10017 (212) 303-1650
MSD Partners, L.P. (Filed by) CIK: 0001514334 (see all company filings)

EIN.: 271522220 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A